Illumina Tells Investors Cancer Samples, Not Sequencing, Are Bottleneck in Dx Initiative
September 29, 2009
Illumina Tells Investors Cancer Samples, Not Sequencing, Are Bottleneck in Dx Initiative
At the UBS Global Life Sciences Conference in New York last week, Illumina President and CEO Jay Flatley also said that the firm is "pleased with" the progress of Oxford Nanopore Technologies, in which it invested $18 million earlier this year.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Illumina Sequencing Revenue Grows 70 Percent in Q4, Driven by HiSeq
February 15, 2011 / In Sequence - Stronger-than-Expected Demand for HiSeq Contributes to 50 Percent Boost in Sequencing Sales for Illumina in Q2
August 3, 2010 / In Sequence - Illumina Pushes Back Shipment Date for iScan Sequencing Module to Q2 2010
September 22, 2009 / In Sequence - Illumina Sees Clinical Applications for MiSeq; Plans FDA Submission in 2012
August 3, 2011 / Clinical Sequencing News - Illumina Books Orders for More than 135 MiSeqs, Starts Early-Access Shipments
August 2, 2011 / In Sequence